Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

electroCore Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Dan Goldberger

İcra Kurulu Başkanı

US$1.3m

Toplam tazminat

CEO maaş yüzdesi	46.9%
CEO görev süresi	5yrs
CEO sahipliği	2.7%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	4.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dan Goldberger'un ücretlendirmesi electroCore'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$1m	US$601k	-US$19m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$998k	US$557k	-US$22m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$1m	US$525k	-US$17m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$920k	US$500k	-US$24m
Sep 30 2020	n/a	n/a	-US$26m
Jun 30 2020	n/a	n/a	-US$32m
Mar 31 2020	n/a	n/a	-US$39m
Dec 31 2019	US$2m	US$125k	-US$45m

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 1.28M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Dan şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Dan Goldberger (65 yo)

5yrs

Görev süresi

US$1,281,333

Tazminat

Mr. Daniel S. Goldberger, also known as Dan, has been Chief Executive Officer and Director of electroCore, Inc. since October 1, 2019. Mr. Goldberger served as Executive Chairman at Repro Med Systems, Inc....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Goldberger	CEO & Director	5yrs	US$1.28m	2.73% $ 1.3m
Thomas Errico	Founder & Independent Director	no data	US$158.13k	3.08% $ 1.4m
Brian Posner	CFO & Corporate Secretary	5.5yrs	US$679.29k	0.10% $ 46.1k
Michael Romaniw	Executive Vice President of Systems & Operations	5.8yrs	Veri yok	Veri yok
Donald Melnikoff	Senior Vice President of Engineering	less than a year	Veri yok	Veri yok
Mitch Deshon	Vice President of Global Sales & Business Development	1.2yrs	Veri yok	Veri yok
Michael Mansfield	Vice President of Marketing	less than a year	Veri yok	Veri yok
Carrie Kochek	Senior Director of Human Resources	3.9yrs	Veri yok	Veri yok
Peter Staats	Chief Medical Officer	4.8yrs	US$1.21m	Veri yok
Joshua Lev	Chief Strategy Officer	2.8yrs	Veri yok	Veri yok
Manuel Marques	Senior Vice President of Operations	1.1yrs	Veri yok	Veri yok
Amanda Yanuklis	Chief of Staff	less than a year	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: ECOR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Goldberger	CEO & Director	5yrs	US$1.28m	2.73% $ 1.3m
Thomas Errico	Founder & Independent Director	19.1yrs	US$158.13k	3.08% $ 1.4m
Thomas Patton	Independent Director	4.5yrs	US$165.50k	0.49% $ 227.1k
Frank Cuneo	Independent Chairman of the Board	4.5yrs	US$210.25k	0.088% $ 40.6k
John Gandolfo	Independent Director	4.5yrs	US$155.83k	0.035% $ 16.2k
Patricia Wilber	Independent Director	2.6yrs	US$151.50k	0.38% $ 177.4k
Julie Bruzzone-Goldstein	Independent Director	2.6yrs	US$150.88k	1.12% $ 518.5k
Charles Theofilos	Independent Director	less than a year	Veri yok	6.59% $ 3.0m

4.5yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ECOR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).

electroCore Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

electroCore, Inc., Annual General Meeting, Sep 03, 2024

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc., Annual General Meeting, Dec 02, 2022

Co-Founder recently bought US$56k worth of stock

Recent updates

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

Consensus estimates of losses per share improve by 10%

Forecast to breakeven in 2026

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

electroCore, Inc. to Report Q2, 2024 Results on Aug 07, 2024

electroCore, Inc., Annual General Meeting, Sep 03, 2024

electroCore Announces the Commercial Launch of TAC-STIM™?

Forecast to breakeven in 2026

electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. has announced a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of Gastroparesis

electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023

electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder

electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

electroCore, Inc. Reiterates Revenue Guidance for the Year 2023

electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023

electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga

electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore sees Q3 revenue below consensus

electroCore is issued 4 new U.S. patents in nVNS therapy

electroCore, Inc., Annual General Meeting, Dec 02, 2022

electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022

electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022

electroCore sees Q2 revenue estimate higher than consensus

Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid Syndrome

electroCore Announces Listing Transfer to the Nasdaq Capital Market

Co-Founder recently bought US$56k worth of stock

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

High number of new directors

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022

High number of new directors

Consensus EPS estimates fall by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Price target decreased to US$2.80

electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022

electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus

electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021

electroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

electroCore: Pioneering Bioelectronic Medicine

Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)

Consensus forecasts updated

electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021

electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

electroCore completes sale of $1.4M of NOL tax benefits

electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease Patients

electroCore, Inc. Develops Non-Drug and Non-Invasive Alternative to Pharmaceuticals That Safely and Effectively Stimulates the Vagus Nerve to Communicate with the Brain and Help Optimize the Body’s Own Ability to Control Problems Impacting Its Health

Price target decreased to US$3.50